Several countries have shown progress. Sweden’s strict antibiotic stewardship programmes have reduced usage by 40% since 1995 while maintaining low resistance rates. Similarly, the UK’s ‘Netflix model’—a fixed annual fee for unlimited access to a new antibiotic—has encouraged development. However, in low- and middle-income countries, where sanitation is poor and antibiotics are sold over the counter, the problem is escalating fastest. Without coordinated global action, the post-antibiotic era—where minor scrapes could once again become deadly—is not science fiction but a foreseeable reality. QUESTIONS Questions 1–5 Do the following statements agree with the information given in the reading passage?
The pharmaceutical industry has also contributed to the problem. Developing new antibiotics is expensive and, paradoxically, not very profitable. Since antibiotics are used for short durations and must be reserved to prevent resistance, companies struggle to recoup research costs. Consequently, the antibiotic pipeline has dried up. While 40 new antibiotics were approved between 1980 and 2000, only 12 have been approved since 2010. The World Health Organization (WHO) has identified a ‘priority pathogen list’ of bacteria—including carbapenem-resistant Acinetobacter and drug-resistant tuberculosis—for which no effective drugs remain in development. Several countries have shown progress
Antibiotic resistance occurs when bacteria evolve mechanisms to survive exposure to drugs designed to kill them. This is a natural evolutionary process, but human activities have dramatically accelerated it. The primary driver is the overuse and misuse of antibiotics. In many countries, antibiotics are available without prescription, leading to self-medication for viral infections like the common cold—against which they are useless. Even when prescribed correctly, patients often fail to complete the full course, allowing surviving bacteria to develop resistance. The pharmaceutical industry has also contributed to the